Affiliation:
1. CNC-Center for Neuroscience and Cell Biology, UC-Biotech, University of Coimbra, Biocant Park, Cantanhede, Portugal
2. Clinica Medica “A. Murri”, Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro” Medical School, Bari, Italy
Abstract
Background:
Cardiovascular diseases (CVDs) are a leading risk factor for mortality worldwide and the
number of CVDs victims is predicted to rise through 2030. While several external parameters (genetic, behavioral,
environmental and physiological) contribute to cardiovascular morbidity and mortality; intrinsic metabolic
and functional determinants such as insulin resistance, hyperglycemia, inflammation, high blood pressure and
dyslipidemia are considered to be dominant factors.
Methods:
Pubmed searches were performed using different keywords related with mitochondria and cardiovascular
disease and risk. In vitro, animal and human results were extracted from the hits obtained.
Results:
High cardiac energy demand is sustained by mitochondrial ATP production, and abnormal mitochondrial
function has been associated with several lifestyle- and aging-related pathologies in the developed world such as
diabetes, non-alcoholic fatty liver disease (NAFLD) and kidney diseases, that in turn can lead to cardiac injury. In
order to delay cardiac mitochondrial dysfunction in the context of cardiovascular risk, regular physical activity
has been shown to improve mitochondrial parameters and myocardial tolerance to ischemia-reperfusion (IR).
Furthermore, pharmacological interventions can prevent the risk of CVDs. Therapeutic agents that can target
mitochondria, decreasing ROS production and improve its function have been intensively researched. One example
is the mitochondria-targeted antioxidant MitoQ10, which already showed beneficial effects in hypertensive rat
models. Carvedilol or antidiabetic drugs also showed protective effects by preventing cardiac mitochondrial oxidative
damage.
Conclusion:
This review highlights the role of mitochondrial dysfunction in CVDs, also show-casing several
approaches that act by improving mitochondrial function in the heart, contributing to decrease some of the risk
factors associated with CVDs.
Funder
European Union’s Horizon 2020 Research and Innovation programme
Foundation for Science and Technology
Operational Programme Competitiveness
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology
Reference265 articles.
1. Global health estimates: deaths and causes, age, sex and country World Health Organization2014
2. Kearney P.M.; Whelton M.; Reynolds K.; Muntner P.; Whelton P.K.; He J.; Global burden of hypertension: Analysis of worldwide data. Lancet 2005,365(9455),217-223
3. Celermajer D.S.; Chow C.K.; Marijon E.; Anstey N.M.; Woo K.S.; Cardiovascular disease in the developing world: Prevalences, patterns, and the potential of early disease detection. J Am Coll Cardiol 2012,60(14),1207-1216
4. Mathers C.D.; Salomon J.A.; Ezzati M.; Begg S.; Vander Hoorn S.; Lopez A.D.; Sensitivity and uncertainty analyses for burden of disease and risk factor estimates. Global Burden of Disease and Risk Factors Chapter 5.2006
5. Dzau V.J.; Antman E.M.; Black H.R.; The cardiovascular disease continuum validated: Clinical evidence of improved patient outcomes: Part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006,114(25),2850-2870
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献